CEV chemotherapy
ApprovedSmall molecule
CEV chemotherapy is one of 33 small molecule programs targeting Retinoblastoma. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Retinoblastoma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
Vepesid
AAvyxa
Phase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Hycamtin
MMeitheal
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Oncovin
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CEV chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSun Yat-sen University